CD4 News and Research

RSS

VAC-3S immunotherapeutic vaccine for HIV completes first clinical development phase

InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, has just announced successful completion of the first clinical development phase for VAC-3S immunotherapy in the treatment of HIV infections.

30 Nov 2012

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Inovio Pharmaceuticals, Inc. announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon DNA vaccine to treat this virus that causes infant death and congenital abnormalities, is associated with cerebral palsy and brain tumors, and is the most common viral infection in organ transplant recipients. CMV is also associated with numerous inflammatory diseases and cancers, and is implicated in hypertension, a major risk factor for cardiovascular diseases.

26 Nov 2012

Lymphopenia driven diseases and the orphan drug industry: an interview with Damian Marron, CEO of Cytheris

Lymphopenia is when you lack the T cells of your immune system. T cells are very important for controlling infection. Probably the most known cause of lymphopenia is HIV.

23 Nov 2012

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

Immunomic Therapeutics, Inc., a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan.

9 Nov 2012

NJH researchers discover novel target for treatment of food allergies

Researchers at National Jewish Health have discovered a novel target for the treatment of food allergies. Erwin Gelfand, MD, and his colleagues report in the October 2012 issue of the Journal of Allergy and Clinical Immunology that levels of the enzyme Pim 1 kinase rise in the small intestines of peanut-allergic mice. Inhibiting activity of Pim 1 markedly reduced the allergic response to peanuts.

2 Nov 2012

RUB-medical researchers receive $2.3M Gates Foundation grant for HIV vaccine research

To support their research for a vaccine against the HI-Virus, Prof. Dr. Klaus Überla of the Faculty for Medicine at the Ruhr-Universität Bochum and his research team will receive $2.3 million in funding within the next three years from the Bill & Melinda Gates Foundation. The scientists are part of the Collaboration for AIDS Vaccine Discovery (CAVD), which seeks to speed up the development of an HIV-vaccine through a rigorous exchange of information, methods and reagents.

29 Oct 2012

Associated Press examines access to antiretroviral treatment in Myanmar

The Associated Press examines access to antiretroviral treatment in Myanmar, which "ranks among the world's hardest places to get HIV care, and health experts warn it will take years to prop up a broken health system hobbled by decades of neglect."

26 Oct 2012

New findings on how OX40 activation affects T helper cells that target melanoma

Cancers arise in the body all the time. Most are nipped in the bud by the immune response, not least by its T cells, which detect telltale molecular markers-or antigens-on cancer cells and destroy them before they grow into tumors. Cancer cells, for their part, evolve constantly to evade such assassination. Those that succeed become full-blown malignancies. Yet, given the right sort of help, the immune system can destroy even these entrenched tumors.

25 Oct 2012

PLoS ONE publishes review of AntiViral-HyperActivation Limiting Therapeutics clinical trial

ViroStatics, a private Italian/American biopharmaceutical company developing novel therapeutics for viral and other chronic diseases, announced that a review of the first human clinical trial to test a new class of anti-HIV medications known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) has been published in the peer-reviewed journal PLoS ONE.

22 Oct 2012

Babies born to HIV positive mothers more likely to acquire measles

Non-infected babies born to HIV positive mothers should be vaccinated early against measles, to avoid them acquiring the virus or passing it on to others.

19 Oct 2012

Weill Cornell Medical College researcher wins 2012 William B. Coley Award

Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and provost for medical affairs of Cornell University, is a winner of the 2012 William B. Coley Award for Distinguished Research in Basic Immunology from the Cancer Research Institute for her outstanding achievements in immunology and cancer research.

19 Oct 2012

CytoDyn announces update on feline immunodeficiency virus therapeutic antibody program

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it is presenting an update on its Feline Immunodeficiency Virus (FIV) therapeutic antibody program at the 19th West Coast Retrovirus meeting in Palm Springs, California.

8 Oct 2012

Assisted reproduction technology may increase risk of MS activity among women

Researchers in Argentina report that women with multiple sclerosis (MS) who undergo assisted reproduction technology (ART) infertility treatment are at risk for increased disease activity.

4 Oct 2012

Mothers’ CD4 cells ‘remember’ their babies

A breakthrough in understanding a mother’s immune response during pregnancy suggests a new direction for treating autoimmune diseases.

2 Oct 2012

Novel method could help advance fight against persistent 'HIV latency'

Scientists at the Gladstone Institutes have gotten us one step closer to understanding and overcoming one of the least-understood mechanisms of HIV infection-by devising a method to precisely track the life cycle of individual cells infected with HIV, the virus that causes AIDS.

12 Sep 2012

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Sangamo BioSciences, Inc. announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

11 Sep 2012

S. African, S. Korean research team developing smartphone HIV testing device, application

Researchers from South Africa and South Korea are developing a smartphone-based device and application able to "photograph and analyze blood samples in areas far from laboratories to diagnose HIV and even measure the health of [patients'] immune systems," Agence France-Presse reports.

5 Sep 2012

Study finds increase in HIV treatment use in the U.S.

Between 2000 and 2008, the proportion of HIV-infected patients in the U.S. receiving effective treatment known as highly active antiretroviral therapy (HAART) increased, and HIV-infected patients appeared to be less infectious and have healthier immune systems at death, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

4 Sep 2012

Brazil expanding national HIV treatment program to include patients with higher CD4 cell counts

Brazil is expanding its national HIV/AIDS treatment program to include about 35,000 additional people, the Associated Press/Seattle Times reports. "Ronaldo Hallal of the health ministry's Sexually Transmitted Disease Department said people with 500 or fewer CD4 cells per cubic millimeter will receive antiretroviral HIV treatment," increasing the cutoff from 350 or less CD4 cells per cubic millimeter prior to the expansion, the news service writes.

31 Aug 2012

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Sleep disorders are a large area. We are focused on one particular type of sleep disturbance called “non-restorative” sleep. People with this problem do sleep, but they don’t wake up feeling refreshed or feeling that their sleep has had the restorative effects of healthy sleep.

29 Aug 2012